Cargando…
Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial
Objective To determine if it is possible to stabilise the cerebral oxygenation of extremely preterm infants monitored by cerebral near infrared spectroscopy (NIRS) oximetry. Design Phase II randomised, single blinded, parallel clinical trial. Setting Eight tertiary neonatal intensive care units in e...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283997/ https://www.ncbi.nlm.nih.gov/pubmed/25569128 http://dx.doi.org/10.1136/bmj.g7635 |
_version_ | 1782351354876919808 |
---|---|
author | Hyttel-Sorensen, Simon Pellicer, Adelina Alderliesten, Thomas Austin, Topun van Bel, Frank Benders, Manon Claris, Olivier Dempsey, Eugene Franz, Axel R Fumagalli, Monica Gluud, Christian Grevstad, Berit Hagmann, Cornelia Lemmers, Petra van Oeveren, Wim Pichler, Gerhard Plomgaard, Anne Mette Riera, Joan Sanchez, Laura Winkel, Per Wolf, Martin Greisen, Gorm |
author_facet | Hyttel-Sorensen, Simon Pellicer, Adelina Alderliesten, Thomas Austin, Topun van Bel, Frank Benders, Manon Claris, Olivier Dempsey, Eugene Franz, Axel R Fumagalli, Monica Gluud, Christian Grevstad, Berit Hagmann, Cornelia Lemmers, Petra van Oeveren, Wim Pichler, Gerhard Plomgaard, Anne Mette Riera, Joan Sanchez, Laura Winkel, Per Wolf, Martin Greisen, Gorm |
author_sort | Hyttel-Sorensen, Simon |
collection | PubMed |
description | Objective To determine if it is possible to stabilise the cerebral oxygenation of extremely preterm infants monitored by cerebral near infrared spectroscopy (NIRS) oximetry. Design Phase II randomised, single blinded, parallel clinical trial. Setting Eight tertiary neonatal intensive care units in eight European countries. Participants 166 extremely preterm infants born before 28 weeks of gestation: 86 were randomised to cerebral NIRS monitoring and 80 to blinded NIRS monitoring. The only exclusion criterion was a decision not to provide life support. Interventions Monitoring of cerebral oxygenation using NIRS in combination with a dedicated treatment guideline during the first 72 hours of life (experimental) compared with blinded NIRS oxygenation monitoring with standard care (control). Main outcome measures The primary outcome measure was the time spent outside the target range of 55-85% for cerebral oxygenation multiplied by the mean absolute deviation, expressed in %hours (burden of hypoxia and hyperoxia). One hour with an oxygenation of 50% gives 5%hours of hypoxia. Secondary outcomes were all cause mortality at term equivalent age and a brain injury score assessed by cerebral ultrasonography. Randomisation Allocation sequence 1:1 with block sizes 4 and 6 in random order concealed for the investigators. The allocation was stratified for gestational age (<26 weeks or ≥26 weeks). Blinding Cerebral oxygenation measurements were blinded in the control group. All outcome assessors were blinded to group allocation. Results The 86 infants randomised to the NIRS group had a median burden of hypoxia and hyperoxia of 36.1%hours (interquartile range 9.2-79.5%hours) compared with 81.3 (38.5-181.3) %hours in the control group, a reduction of 58% (95% confidence interval 35% to 73%, P<0.001). In the experimental group the median burden of hypoxia was 16.6 (interquartile range 5.4-68.1) %hours, compared with 53.6 (17.4-171.3) %hours in the control group (P=0.0012). The median burden of hyperoxia was similar between the groups: 1.2 (interquartile range 0.3-9.6) %hours in the experimental group compared with 1.1 (0.1-23.4) %hours in the control group (P=0.98). We found no statistically significant differences between the two groups at term corrected age. No severe adverse reactions were associated with the device. Conclusions Cerebral oxygenation was stabilised in extremely preterm infants using a dedicated treatment guideline in combination with cerebral NIRS monitoring. Trial registration ClinicalTrial.gov NCT01590316. |
format | Online Article Text |
id | pubmed-4283997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-42839972015-01-08 Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial Hyttel-Sorensen, Simon Pellicer, Adelina Alderliesten, Thomas Austin, Topun van Bel, Frank Benders, Manon Claris, Olivier Dempsey, Eugene Franz, Axel R Fumagalli, Monica Gluud, Christian Grevstad, Berit Hagmann, Cornelia Lemmers, Petra van Oeveren, Wim Pichler, Gerhard Plomgaard, Anne Mette Riera, Joan Sanchez, Laura Winkel, Per Wolf, Martin Greisen, Gorm BMJ Research Objective To determine if it is possible to stabilise the cerebral oxygenation of extremely preterm infants monitored by cerebral near infrared spectroscopy (NIRS) oximetry. Design Phase II randomised, single blinded, parallel clinical trial. Setting Eight tertiary neonatal intensive care units in eight European countries. Participants 166 extremely preterm infants born before 28 weeks of gestation: 86 were randomised to cerebral NIRS monitoring and 80 to blinded NIRS monitoring. The only exclusion criterion was a decision not to provide life support. Interventions Monitoring of cerebral oxygenation using NIRS in combination with a dedicated treatment guideline during the first 72 hours of life (experimental) compared with blinded NIRS oxygenation monitoring with standard care (control). Main outcome measures The primary outcome measure was the time spent outside the target range of 55-85% for cerebral oxygenation multiplied by the mean absolute deviation, expressed in %hours (burden of hypoxia and hyperoxia). One hour with an oxygenation of 50% gives 5%hours of hypoxia. Secondary outcomes were all cause mortality at term equivalent age and a brain injury score assessed by cerebral ultrasonography. Randomisation Allocation sequence 1:1 with block sizes 4 and 6 in random order concealed for the investigators. The allocation was stratified for gestational age (<26 weeks or ≥26 weeks). Blinding Cerebral oxygenation measurements were blinded in the control group. All outcome assessors were blinded to group allocation. Results The 86 infants randomised to the NIRS group had a median burden of hypoxia and hyperoxia of 36.1%hours (interquartile range 9.2-79.5%hours) compared with 81.3 (38.5-181.3) %hours in the control group, a reduction of 58% (95% confidence interval 35% to 73%, P<0.001). In the experimental group the median burden of hypoxia was 16.6 (interquartile range 5.4-68.1) %hours, compared with 53.6 (17.4-171.3) %hours in the control group (P=0.0012). The median burden of hyperoxia was similar between the groups: 1.2 (interquartile range 0.3-9.6) %hours in the experimental group compared with 1.1 (0.1-23.4) %hours in the control group (P=0.98). We found no statistically significant differences between the two groups at term corrected age. No severe adverse reactions were associated with the device. Conclusions Cerebral oxygenation was stabilised in extremely preterm infants using a dedicated treatment guideline in combination with cerebral NIRS monitoring. Trial registration ClinicalTrial.gov NCT01590316. BMJ Publishing Group Ltd. 2015-01-05 /pmc/articles/PMC4283997/ /pubmed/25569128 http://dx.doi.org/10.1136/bmj.g7635 Text en © Hyttel-Sorensen et al 2015 http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Research Hyttel-Sorensen, Simon Pellicer, Adelina Alderliesten, Thomas Austin, Topun van Bel, Frank Benders, Manon Claris, Olivier Dempsey, Eugene Franz, Axel R Fumagalli, Monica Gluud, Christian Grevstad, Berit Hagmann, Cornelia Lemmers, Petra van Oeveren, Wim Pichler, Gerhard Plomgaard, Anne Mette Riera, Joan Sanchez, Laura Winkel, Per Wolf, Martin Greisen, Gorm Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial |
title | Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial |
title_full | Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial |
title_fullStr | Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial |
title_full_unstemmed | Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial |
title_short | Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial |
title_sort | cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase ii randomised clinical trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283997/ https://www.ncbi.nlm.nih.gov/pubmed/25569128 http://dx.doi.org/10.1136/bmj.g7635 |
work_keys_str_mv | AT hyttelsorensensimon cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT pelliceradelina cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT alderliestenthomas cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT austintopun cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT vanbelfrank cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT bendersmanon cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT clarisolivier cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT dempseyeugene cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT franzaxelr cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT fumagallimonica cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT gluudchristian cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT grevstadberit cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT hagmanncornelia cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT lemmerspetra cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT vanoeverenwim cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT pichlergerhard cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT plomgaardannemette cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT rierajoan cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT sanchezlaura cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT winkelper cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT wolfmartin cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial AT greisengorm cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial |